Arcus Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

On May 27, 2020 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, reported that it has commenced an underwritten public offering of its common stock (Press release, Arcus Biosciences, MAY 27, 2020, View Source [SID1234558578]). The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Arcus Biosciences. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup, SVB Leerink and Evercore Group LLC are acting as joint book running managers for the proposed offering.

A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the prospectus related to the offering may be obtained, when available, from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at (800) 831-9146; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Sierra Oncology Announces Presentations at Upcoming Investor Conferences

On May 27, 2020 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported that Dr. Barbara Klencke, Chief Development Officer, will present the company at the upcoming Jefferies Global Virtual Healthcare Conference and at the Oppenheimer Biotech by the Lake 2020 Investor Summit (Press release, Sierra Oncology, MAY 27, 2020, View Source [SID1234558527]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Conference:

Oppenheimer Biotech by the Lake 2020 Investor Summit

Date:

Thursday, May 28, 2020

Time:

11:25 am. ET

Conference:

Jefferies Global Virtual Healthcare Conference

Date:

Wednesday, June 3, 2020

Time:

4:30 p.m. ET

Webcast:

Listen to a live audio webcast or archive of this presentation at www.sierraoncology.com.

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

On May 27, 2020 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering (Press release, BioCryst Pharmaceuticals, MAY 27, 2020, https://biocryst.gcs-web.com/news-releases/news-release-details/biocryst-commences-public-offering-common-stock-and-pre-funded [SID1234558543]). As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

J.P. Morgan and Piper Sandler are acting as joint book-running managers for the offering.

All of the securities to be sold in the offering are being sold by BioCryst, with the proceeds to be used for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory, pre-launch and commercial activities for the prophylactic berotralstat (BCX7353) program in the United States and European Union; advancement of the worldwide development, manufacturing, regulatory and clinical activities for BCX9930 for complement-mediated diseases; post-approval commitments for RAPIVABTM/ALPIVABTM; and capital expenditures and other general working capital needs.

A shelf registration statement on Form S-3 relating to the securities being offered by BioCryst has been previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

This offering is being made by means of a prospectus supplement and related prospectus. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-866-803-9204, or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email at [email protected].

Pacira BioSciences to Present at the 2020 Jefferies Virtual Healthcare Conference

On May 27, 2020 Pacira BioSciences, Inc. (NASDAQ: PCRX) reported that it will present at the 2020 Jefferies Virtual Healthcare Conference at 9:30 AM ET on Wednesday, June 3, 2020 (Press release, Pacira Pharmaceuticals, MAY 27, 2020, View Source [SID1234558561]). Live audio of the event can be accessed by visiting the "Events" page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


MedX Health Corp. provides update on the release of its Annual Financial Statements and related Disclosures for fiscal 2019 and postponement of release of its First Quarter 2020 Interim Financial Statements and related Disclosures

On May 27, 2020 MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) reported an update on the filing of its Annual Financial Statements and related Disclosures (the "Annual Disclosures") for the year ended December 31, 2019, following the earlier announcement in its Press Release dated April 28, 2020, that filing of the Annual Disclosures would be delayed due to COVID-19 related delays (Press release, MedX Health, MAY 27, 2020, View Source [SID1234558579]). The Company is continuing to work diligently and expeditiously with its auditors, and anticipates that the Annual Disclosures will be filed by June 12, 2020, as previously indicated.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company further announces that filing of the Interim Financial Statements and related Disclosures for the three-month period ended March 31, 2020, the First Quarter of fiscal 2020 (the "Interim Disclosures") will also be delayed owing to COVID-19 related issues. The Company anticipates that the Interim Disclosures will be filed by July 13, 2020.

In relation to the delay in filing of the Annual Disclosures and the Interim Disclosures, MedX relies on the provisions of Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements and corresponding Instruments in the other jurisdictions in which the Company is a reporting issuer.

MedX confirms that there have been no material business developments other than as disclosed in its Press Releases and previous filings, and further confirms that Management and other insiders of the Company have been, since April 28, 2020, and continue to be subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, which will remain in effect until both the Annual Disclosures and the Interim Disclosures have been filed.